The use of research abstracts in formulary decision making by the joint oncology drug review of Canada

Applied Health Economics and Health Policy

Volumn 8, Issue 6, 2010, Pages 387-391

  Weizman, Adam V ^a   Griesman, Josh ^b   Bell, Chaim M ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; Decision making; Evidence based medicine; Formularies

Indexed keywords

ARTICLE; CANADA; CANCER RESEARCH; CLINICAL RESEARCH; DECISION MAKING; DRUG APPROVAL; DRUG FORMULARY; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE POLICY; PUBLICATION;

ABSTRACTING AND INDEXING AS TOPIC; ANTINEOPLASTIC AGENTS; CONSENSUS; DECISION MAKING, ORGANIZATIONAL; FORMULARIES AS TOPIC; HUMANS; PHARMACY AND THERAPEUTICS COMMITTEE;

EID: 78049498454     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11530510-000000000-00000     Document Type: Article

References (12)

1. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003 Jul 23; 290 (4): 495-501
2. Kelly JA. Scientific meeting abstracts: significance, access, and trends. Bull Med Libr Assoc 1998 Jan; 86 (1): 68-76
3. Krzyzanowska MK, Pintilie M, Brezden-Masley C, et al. Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. J Clin Oncol 2004; 22 (10): 1993-9
4. Rubin HR, Redelmeier DA, Wu AW, et al. How reliable is peer review of scientific abstracts? Looking back at the 1991 annual meeting of the Society of General Internal Medicine. J Gen Intern Med 1993 May; 8 (5): 255-8
5. Preston CF, Bhandari M, Fulkerson E, et al. The consistency between scientific papers presented at the Orthopaedic Trauma Association and their subsequent full-text publication. J Orthop Trauma 2006; 20: 129-33
6. Dhaliwal U, Kumar R. An observational study of the proceedings of the All India Ophthalmological Conference, 2000 and subsequent publication in indexed journals. Indian J Ophthalmol 2008 May-Jun; 56 (3): 189-95
7. PausJenssen AM, Singer PA, Detsky AS. Ontario's Formulary Committee: how recommendations are made. Pharma-coeconomics 2003; 21 (4): 285-94
8. Pater JL, Browman GP, Brouwers MC, et al. Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. J Clin Onc 2001 Jul 15; 19 (14): 3392-6
9. Hirschfeld S, Pazdur R. Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 2002; 42 (2): 137-43
10. Rosmarakis ES, Stoeriades ES, Vergidis PI, et al. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J 2005 May; 19: 673-80
11. Cook DJ, Guyatt GH, Ryan G, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993 Jun 2; 269 (21): 2749-53
12. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ 2002 Jan 8; 166 (1): 44-7